Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service

• CRISPR-based screening technology platform to address critical gaps in target ID and validation • Single cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight

Government changes UK SPC waiver following BIA intervention

The BIA has successfully argued for a significant change in approach to the UK’s Supplementary Protection Certificate (SPC) manufacturing waiver. The BIA’s engagement with the Government was led by Andrew Hutchinson, Partner at Simmons and Simmons and member of the BIA’s Intellectual Property Advisory Committee (IPAC). Here he provides an update following the Government’s response to the consultation and publication of draft legislation.

Horizon Discovery licenses CHOSOURCE platform to TrueBinding for development and commercialization of multiple biotherapeutics

TrueBinding signs multi-product commercial-use license to develop stable, antibody-expressing cell lines using Horizon’s gene-edited CHO GS knockout platform

Guest Blog|COVID19: Where there’s a will there’s a way

The COVID-19 pandemic has demonstrated the importance of science and the dedication of scientists in overcoming the challenges that we face. At Exploristics, we have been involved in multiple projects relating to the development of new treatments and diagnostics.

CPI, the Cell and Gene Therapy Catapult and MicrofluidX announce development of technology to rapidly scale up cell and gene therapy manufacture

CPI, MicrofluidX and the Cell and Gene Therapy Catapult (CGT Catapult) announced today their collaboration in a project to develop bioprocessing technology for the rapid scale-up of cell and gene therapies.

CEO Update|Monday 27 July

Progress towards the development of COVID-19 vaccines continues as the Cell and Gene Therapy Catapult has stepped up to increase the UK’s capacity and capability to manufacture successful COVID-19 vaccines.

Acacia Pharma Advances Preparations for US Launch of BARHEMSYS®

Second API Supplier for BARHEMSYS® Receives FDA Approval This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.

£30 million Biomedical Catalyst opens for applications following successful BIA campaign

From today, innovative biotech companies will be able to apply for access to a share of £30 million in grant funding through a relaunched Biomedical Catalyst.

Government announces funding for scale up of COVID-19 vaccine with additional investment to support upskilling in Cell and Gene Therapy and Vaccine manufacturing

Today the Department of Business, Energy and Industrial Strategy has awarded £100 million to fund a Cell and Gene Therapy Catapult Manufacturing Innovation Centre to accelerate production of a COVID-19 vaccine in the UK.

Press Release: Over £100m cash boost to manufacture millions of doses of COVID-19 vaccine

- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment - Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills - New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics